Why this matters
WHO preparedness priorities increasingly address strategic stockpiles of essential medical supplies, resilient emergency supply chains, access to therapeutics and geographically diversified local and regional manufacturing. This creates a broader question for oxygen-delivery medicine: how can health systems preserve life-supporting capacity when normal supply systems are disrupted?
Blood supply is a strategic dependency
Donor blood remains indispensable medicine. Its availability depends on donor participation, collection, testing, processing, storage, trained personnel, transport and functioning supply chains. WHO guidance recognizes that infectious-disease outbreaks and emergencies can threaten blood sufficiency and safety and can disrupt donors, critical materials and equipment.
Precision Oxygen Therapeutics based on Biological Hemoglobin Oxygen Carriers could offer a fundamentally different preparedness capability: shelf-stable strategic reserves combined, subject to validation and regulatory qualification, with scalable regional manufacturing capacity.
From stockpiles to sovereign capacity
Strategic preparedness should not be measured only by how much material is stored. The longer-term objective is the ability to store, produce, quality-control and deploy life-supporting oxygen-delivery capacity when and where it is needed.
Ready When Every Minute Matters.
Modular robotic manufacturing
BHOC envisions modular, robotic manufacturing designed for scalable regional deployment, with centralized digital oversight and integrated QA/QC. This proposed approach requires facility-specific engineering, process validation, regulatory qualification, cybersecurity, supply-chain qualification and implementation before deployment.
Oxygen Security
We use Oxygen Security as an emerging BHOC policy concept: the ability of a health system to maintain access to clinically appropriate oxygen-delivery capacity during normal operations, emergencies and major disruptions. Further scientific and policy work is required to determine where oxygen therapeutics may appropriately contribute.
Contextual relevance to BHOC
BHOC is being developed within Precision Oxygen Therapeutics. Long-term development objectives include shelf stability, donor-independent production, compatibility without red-cell blood-group matching by design and scalable manufacturing. These objectives require product-specific analytical, manufacturing, preclinical, clinical and regulatory validation. WHO has not designated BHOC as a medical countermeasure, strategic-stockpile product or pandemic-preparedness technology.
We welcome serious enquiries from governments, healthcare systems, research institutions, manufacturers and strategic partners. Submit your proposal through BHOC Therapeutics. We will review the opportunity and respond where there is a strategic fit.
Submit a Partnership Enquiry →